Business Wire

CGTN

20.3.2021 13:19:10 CET | Business Wire | Press release

Share
CGTN: China Unveils New Discoveries From Sanxingdui, Over 500 Items Unearthed

Chinese archaeologists announced on Saturday that some new major discoveries have been made at the legendary Sanxingdui Ruins site in southwest China, helping shed light on the cultural origins of the Chinese nation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210320005008/en/

Archaeologists have found six new sacrificial pits and unearthed more than 500 items dating back about 3,000 years at the Sanxingdui Ruins in Sichuan Province, the National Cultural Heritage Administration (NCHA) announced in the provincial capital Chengdu.

Over 500 precious cultural relics discovered

Ranging from 3.5 to 19 square meters, these six sacrificial pits, which were discovered from November 2019 to May 2020, are in rectangular shape, according to NCHA. Among them, pits No.3, No.4, No.5 and No.6 have been excavated to the utensil layer so far, while pits No.7 and No.8 are being backfilled.

Together they form an area in which people of the ancient Shu civilization offered sacrifices to heaven, Earth and their ancestors, and prayed for prosperity and peace, according to Tang Fei, head of the excavation team at Sanxingdui and chief of the Sichuan Provincial Cultural Relics and Archaeology Research Institute.

The discoveries have shown the distinctiveness of the Shu civilization and the diversity of the Chinese civilization, said Ran Honglin, another researcher with the institute.

In addition, over 500 pieces of important cultural relics have been unearthed from these six pits, including the fragments of gold masks, bird-shaped gold ornaments, gold foil, painted bronze head portraits, giant bronze masks, bronze sacred tree, ivory, fragments of exquisite tooth carvings, jade cong and jade tools.

A gold mask has been unearthed at the No.5 sacrificial pit. With an area of about three square meters, it is the smallest pit, but it's where the most gold pieces were unearthed, according to archaeologists.

During the process, archaeologists have made full use of modern scientific and technological means to build an archaeological excavation cabin, integrated excavation platform and multi-functional excavation operation system.

With the support of professional teams of multiple disciplines and institutions, they have formed an integrated work mode combining traditional archaeology, laboratory archaeology, technological archaeology as well as the protection of cultural relics. The combination will ensure the high quality and high level of archaeological work, NCHA said at the conference.

Meanwhile, the NCHA has identified the "Research on the Civilization Process of Bashu in Sichuan-Chongqing Region" as a major program of the "Archaeological China" project, aiming to conduct in-depth study on the evolution of civilization in the region and its integration into the overall cultural landscape of the pluralistic unity of the Chinese nation.

Located in the city of Guanghan, some 40 kilometers from Sichuan's provincial capital Chengdu, the Sanxingdui Ruins site is regarded one of the most important archaeological discoveries in the 20th century. The excavation has lasted for nearly 100 years since the first discovery in the late 1920s.

In 1986, archaeologists found two large-scale sacrificial pits dating back to the Shang Dynasty (1600-1046 BC). Thousands of rare treasures were discovered from the two pits.

https://news.cgtn.com/news/2021-03-20/China-unveils-new-discoveries-from-Sanxingdui-YMkx9az0Yg/index.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye